Pamrevlumab is under clinical development by FibroGen and currently in the Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Pamrevlumab’s likelihood of approval (LoA) and phase transition for Pancreatic Ductal Adenocarcinoma took place on 06 Jul 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pamrevlumab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Pamrevlumab (FG-3019) is under development for the treatment of idiopathic pulmonary fibrosis, Duchenne muscular dystrophy and metastatic pancreatic ductal adenocarcinoma (PDAC) or fibrosis involved in pancreatic cancer, liver fibrosis and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is administered as an intravenous infusion. FG-3019 is a fully human recombinant IgG, kappa monoclonal antibody that acts against connective tissue growth factor (CTGF). The drug candidate was also under development for the treatment of systemic sclerosis, microalbuminuria, pneumonia, focal segmental glomerulosclerosis, type I or type II diabetes mellitus, diabetic nephropathy, (diabetic kidney disease) and proteinuria.
FibroGen is a biopharmaceutical company that discovers, and develops medicines for the treatment of anemia, cancer, and fibrotic disease. Its approved product includes roxadustat for the treatment of treatment of anemia associated with chronic kidney disease, in both dialysis-dependent (DD) and non-dialysis-dependent (NDD) patients. Its pipeline product includes pamrevlumab (FG-3019) for the treatment of idiopathic pulmonary fibrosis (IPF), duchenne muscular dystrophy (DMD); ELUMINEX for the treatment of Corneal Blindness. The company is also evaluating pamrevlumab in Phase II for investigating its safety and efficiency in patients with COVID-19. The company has operations in the US, Hong Kong, Finland, Cayman Islands and China. FibroGen is headquartered in San Francisco, California, the US.
Quick View Pamrevlumab LOA Data
|Highest Development Stage|